Navigation Links
Genomma Lab Announces Initiation of Stock Repurchase Fund
Date:1/9/2009

MEXICO CITY, Jan. 9 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), a leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products company announced that on January 12, 2009 it will initiate the operation of a stock repurchase fund according to the terms approved by the Company's Board of Directors for an amount of up to Ps. 100 million pesos.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.

Genomma Lab performed its Initial Public Offering in June, 2008, through a combined offering (mainly primary) and is listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Web Site: www.genommalab.com


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
2. Genomma Lab Announces 2009 Earnings Guidance
3. Genomma Lab Internacional Acquires UNIGASTROZOL
4. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
5. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
6. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
7. VA Announces $22 Million for Rural Veterans
8. Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue
9. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
10. Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference
11. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular SearchLight ... online modeling resource for fluorescence microscopists and optical system designers, enabling The Right ... years spanning the globe, SearchLight has become a tremendously popular tool for the ...
(Date:4/27/2017)... Austin, TX (PRWEB) , ... April 27, 2017 ... ... released its all natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve ... safe, non-toxic deodorant that actually works! , Countless deodorants flood the aisles that ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product ... oil many times purer and more potent than the market has seen before. Swissx ... Switzerland, as well as a patented chromatography process for extraction, to produce its CBD ...
(Date:4/26/2017)... ... 26, 2017 , ... Journal of Oral Implantology – Tooth loss ... overall dental health, including complications with speech, eating, and overcompensation of mouth due to ... lost teeth. As the number of tooth replacements increase, it is imperative to design ...
(Date:4/26/2017)... TX (PRWEB) , ... April 26, 2017 , ... ... confer the distinction of Customer Excellence upon National Registry of Emergency Medical ... “Customer Engagement drives Financial Performance,” said Dr. Jan G. West, Ph.D. , ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: